HLS Therapeutics 향후 성장
Future 기준 점검 4/6
HLS Therapeutics은 연간 수입과 매출이 각각 70.2%와 11.2% 증가할 것으로 예상되고 EPS는 연간 70.8%만큼 증가할 것으로 예상됩니다.
핵심 정보
70.2%
이익 성장률
70.84%
EPS 성장률
| Pharmaceuticals 이익 성장 | 15.0% |
| 매출 성장률 | 11.2% |
| 향후 자기자본이익률 | n/a |
| 애널리스트 커버리지 | Low |
| 마지막 업데이트 | 19 May 2026 |
최근 향후 성장 업데이트
Recent updates
내러티브 업데이트 • Jun 23
HLS: Future Upside Will Depend On Executing Reaffirmed 2026 Earnings Guidance
Analysts have adjusted their CA$5 price target on HLS Therapeutics in light of updated assumptions for revenue growth, profit margins, and future P/E. This reflects a refined view of the stock's potential value.
내러티브 업데이트 • Jun 07
HLS: Future Execution Risks Will Restrain Benefits Of New Franchise And Hold Stance
Analysts have updated their view on HLS Therapeutics with a refined fair value of CA$4.49 per share. This is supported by refreshed assumptions on revenue growth, profit margins, discount rate and future P/E that align with recent Street price targets in the CA$4.45 to CA$5.00 range.내러티브 업데이트 • May 24
HLS: Future Upside Will Depend On Delivering New 2026 Revenue Guidance
Analysts have modestly adjusted their CA$ price target on HLS Therapeutics, with models reflecting a fair value estimate holding close to CA$12.00, supported by recent Hold-rated coverage and slightly lower Street targets around CA$4.45 to CA$5.00. Analyst Commentary Recent Street research on HLS Therapeutics has centered on Hold ratings paired with price targets in the CA$4.45 to CA$5.00 range.내러티브 업데이트 • May 04
HLS: Future Upside Will Depend On Executing Refined Earnings Outlook
Analysts have trimmed their price target on HLS Therapeutics to CA$4.45 from CA$4.75, reflecting updated views on the company that feed into revised assumptions regarding growth, margins and future P/E. Analyst Commentary Recent research updates on HLS Therapeutics show price targets aligning at CA$4.45, with ratings maintained rather than shifted to more negative stances.내러티브 업데이트 • Apr 18
HLS: Future Execution Risks Will Temper Benefits Of New Cholesterol Franchise
Analysts have trimmed their price target on HLS Therapeutics to CA$4.45 from CA$4.75, reflecting updated views on its growth profile and profitability. Analyst Commentary Bearish analysts are signaling a more cautious stance on HLS Therapeutics after the revised CA$4.45 price target.내러티브 업데이트 • Apr 02
HLS: Future Execution Risks Will Offset New Product And Margin Assumptions
Analysts have trimmed their price target on HLS Therapeutics to CA$4.45 from CA$4.75, reflecting updated views on the company’s revenue growth potential, profit margin outlook, and a higher assumed future P/E multiple. Analyst Commentary Bearish analysts have reacted to recent developments by trimming their price target on HLS Therapeutics to CA$4.45 from CA$4.75, while maintaining a Hold stance.내러티브 업데이트 • Mar 18
HLS: Future Share Performance Will Rely On Execution Against Updated Outlook
The analyst price target for HLS Therapeutics has been reduced by CA$0.30 to CA$4.45. Analysts cited updated assumptions around growth, profitability and valuation multiples as key drivers for the change.내러티브 업데이트 • Mar 03
HLS: Fair Outlook Will Balance Revised Profitability Assumptions And Execution Risks
Analysts have trimmed their price target on HLS Therapeutics to CA$4.72 from CA$4.76, reflecting updated assumptions around discount rates, revenue growth, profit margins, and a slightly lower future P/E multiple. Valuation Changes Fair Value: CA$ fair value estimate adjusted slightly from CA$4.76 to CA$4.72.내러티브 업데이트 • Feb 17
HLS: Improved Profitability Outlook Will Support Stronger Future Share Performance
Analysts now see fair value for HLS Therapeutics at about CA$11.59, slightly below the prior CA$11.79. This reflects updated assumptions around discount rate, revenue growth, profit margin and future P/E expectations.내러티브 업데이트 • Feb 03
HLS: Higher Profitability Outlook Will Support Upgraded Future Share Performance
Analysts have nudged their price target on HLS Therapeutics higher to C$7 from C$6, pointing to updated assumptions on revenue growth, profit margins and future P/E levels that support a slightly revised outlook for the shares. Analyst Commentary Recent Street research reflects a slightly more optimistic tone around HLS Therapeutics, with bullish analysts adjusting their models to support a higher valuation anchor for the shares.내러티브 업데이트 • Jan 20
HLS: Higher Profitability Outlook Will Drive Stronger Future Share Performance
Analysts have raised their price target on HLS Therapeutics to C$7 from C$6, reflecting updated views on fair value, growth expectations, profitability, and future P/E assumptions. Analyst Commentary Recent Street research points to a more constructive view on HLS Therapeutics, with bullish analysts revisiting their assumptions on fair value, growth potential, and what they are willing to pay on a P/E basis.내러티브 업데이트 • Jan 06
HLS: Higher Rating Outlook Will Balance Execution Risks And Near Term Guidance
Analysts lifted their price target for HLS Therapeutics to C$7 from C$6, citing updated assumptions around fair value, discount rate, revenue growth, profit margins and a lower future P/E multiple in their models. Analyst Commentary Even with the price target now set at C$7, some research commentary still reads as cautious.내러티브 업데이트 • Dec 14
HLS: Higher Projected Earnings Will Support Stronger Future Share Performance
Analysts have raised their price target on HLS Therapeutics by C$1 to C$7, reflecting higher projected fair value, faster expected revenue growth, and improved profit margin assumptions, despite a slightly higher discount rate and lower future P/E multiple. Analyst Commentary Bullish analysts highlight that the higher price target reflects growing confidence in HLS Therapeutics execution and earnings trajectory, even after factoring in a modestly higher risk profile.
내러티브 업데이트 • Nov 19
HLS: Ongoing Share Buybacks And Debt Reduction Will Drive Positive Momentum
The analyst price target for HLS Therapeutics has increased from C$6 to C$7. This reflects analysts’ confidence in the company’s improving financial performance and ongoing strategic initiatives.분석 기사 • Nov 16
HLS Therapeutics Inc. (TSE:HLS) Just Reported, And Analysts Assigned A CA$6.80 Price Target
The analysts might have been a bit too bullish on HLS Therapeutics Inc. ( TSE:HLS ), given that the company fell short...내러티브 업데이트 • Sep 25
Canadian Regulatory Approvals Will Foster A Vibrant Cardiovascular Market
Analysts have raised their price target for HLS Therapeutics to CA$7.41, citing positive impacts from share buybacks, debt reduction, and an expanding product portfolio, alongside signs of adjusted EBITDA recovery and improved operational performance. Analyst Commentary Share buybacks and debt reduction are viewed positively for capital allocation and balance sheet strength.
새로운 내러티브 • Apr 07
Vascepa Sales In Canada And Cost Cuts Will Transform Prospects
Significant revenue growth is expected from Vascepa in Canada, driven by increased prescriptions and stabilizing payer mix, positively impacting revenue.분석 기사 • Oct 26
Are Investors Undervaluing HLS Therapeutics Inc. (TSE:HLS) By 45%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, HLS Therapeutics fair value estimate is CA$6.42 Current share...분석 기사 • Sep 28
Pinning Down HLS Therapeutics Inc.'s (TSE:HLS) P/S Is Difficult Right Now
It's not a stretch to say that HLS Therapeutics Inc.'s ( TSE:HLS ) price-to-sales (or "P/S") ratio of 1.5x right now...분석 기사 • May 12
Analysts Have Lowered Expectations For HLS Therapeutics Inc. (TSE:HLS) After Its Latest Results
It's shaping up to be a tough period for HLS Therapeutics Inc. ( TSE:HLS ), which a week ago released some...분석 기사 • Apr 14
After Leaping 29% HLS Therapeutics Inc. (TSE:HLS) Shares Are Not Flying Under The Radar
The HLS Therapeutics Inc. ( TSE:HLS ) share price has done very well over the last month, posting an excellent gain of...분석 기사 • Apr 06
Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • Nov 16
Analysts Are More Bearish On HLS Therapeutics Inc. (TSE:HLS) Than They Used To Be
Market forces rained on the parade of HLS Therapeutics Inc. ( TSE:HLS ) shareholders today, when the analysts...분석 기사 • Sep 13
Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • May 05
Would HLS Therapeutics (TSE:HLS) Be Better Off With Less Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...분석 기사 • Apr 05
HLS Therapeutics (TSE:HLS) Is Due To Pay A Dividend Of $0.05
The board of HLS Therapeutics Inc. ( TSE:HLS ) has announced that it will pay a dividend on the 15th of June, with...분석 기사 • Mar 20
HLS Therapeutics (TSE:HLS) Is Paying Out A Dividend Of $0.05
The board of HLS Therapeutics Inc. ( TSE:HLS ) has announced that it will pay a dividend on the 15th of June, with...이익 및 매출 성장 예측
| 날짜 | 매출 | 이익 | 자유현금흐름 | 영업현금흐름 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2028 | 77 | 3 | N/A | N/A | 2 |
| 12/31/2027 | 64 | -1 | N/A | N/A | 3 |
| 12/31/2026 | 58 | -6 | 11 | 11 | 4 |
| 3/31/2026 | 56 | -10 | 18 | 20 | N/A |
| 12/31/2025 | 56 | -12 | 15 | 17 | N/A |
| 9/30/2025 | 56 | -14 | 12 | 14 | N/A |
| 6/30/2025 | 56 | -15 | 12 | 13 | N/A |
| 3/31/2025 | 57 | -18 | 24 | 11 | N/A |
| 12/31/2024 | 57 | -20 | 21 | 8 | N/A |
| 9/30/2024 | 57 | -22 | 22 | 9 | N/A |
| 6/30/2024 | 59 | -24 | 26 | 12 | N/A |
| 3/31/2024 | 61 | -28 | 12 | 13 | N/A |
| 12/31/2023 | 63 | -28 | 16 | 16 | N/A |
| 9/30/2023 | 63 | -29 | 15 | 16 | N/A |
| 6/30/2023 | 63 | -26 | 4 | 14 | N/A |
| 3/31/2023 | 62 | -26 | 5 | 15 | N/A |
| 12/31/2022 | 61 | -24 | 7 | 17 | N/A |
| 9/30/2022 | 61 | -21 | 7 | 17 | N/A |
| 6/30/2022 | 61 | -19 | 16 | 17 | N/A |
| 3/31/2022 | 60 | -12 | 12 | 15 | N/A |
| 12/31/2021 | 60 | -13 | 12 | 16 | N/A |
| 9/30/2021 | 61 | -16 | 11 | 18 | N/A |
| 6/30/2021 | 59 | -16 | -22 | 17 | N/A |
| 3/31/2021 | 57 | -20 | -28 | 11 | N/A |
| 12/31/2020 | 56 | -15 | -35 | 9 | N/A |
| 9/30/2020 | 54 | -20 | -41 | 6 | N/A |
| 6/30/2020 | 54 | -21 | -9 | 10 | N/A |
| 3/31/2020 | 55 | -16 | 4 | 23 | N/A |
| 12/31/2019 | 54 | -20 | N/A | 26 | N/A |
| 9/30/2019 | 57 | -7 | N/A | 35 | N/A |
| 6/30/2019 | 59 | -25 | N/A | 35 | N/A |
| 3/31/2019 | 61 | -24 | N/A | 28 | N/A |
| 12/31/2018 | 61 | -25 | N/A | 33 | N/A |
| 9/30/2018 | 65 | -26 | N/A | 30 | N/A |
| 6/30/2018 | 70 | -8 | N/A | 33 | N/A |
| 3/31/2018 | 73 | -8 | N/A | 37 | N/A |
| 12/31/2017 | 75 | -6 | N/A | 27 | N/A |
| 9/30/2017 | 71 | -11 | N/A | 25 | N/A |
| 12/31/2016 | 54 | -15 | N/A | 22 | N/A |
| 12/31/2015 | 20 | -10 | N/A | -6 | N/A |
애널리스트 향후 성장 전망
수입 대 저축률: HLS 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(3%)보다 빠른 성장으로 간주됩니다.
수익 vs 시장: HLS (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.
고성장 수익: HLS 향후 3년 내에 수익을 낼 것으로 예상됩니다.
수익 대 시장: HLS 의 수익(연간 11.2%)이 Canadian 시장(연간 4.5%)보다 빠르게 성장할 것으로 예상됩니다.
고성장 매출: HLS 의 수익(연간 11.2%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.
주당순이익 성장 예측
향후 자기자본이익률
미래 ROE: HLS의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.
성장 기업 찾아보기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/07/19 21:55 |
| 종가 | 2026/07/17 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
HLS Therapeutics Inc.는 4명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| David Martin | Bloom Burton & Co. |
| Tania Armstrong-Whitworth | Canaccord Genuity |
| Michael Freeman | Raymond James Ltd. |